Local and Global News
FoodBev, today named VitaFiber® IMO, a healthy alternative to sugar, as the world's top beverage ingredient. VitaFiber and other award winners were announced at the 18th Annual World Beverage Innovation Awards in Nuremberg.
Edmonton-based companies MACH32 and Andau Medical bring to market an aerosol containment device to reduce risk of COVID-19 exposure for healthcare personnel and patients.
November 6, 2020: BioAlberta Submission to the House of Commons Standing Committee on Health (HESA).
An American judging panel has chosen a Canadian fibre product as a finalist for the 2020 U.S 'Prebiotic Ingredient of the Year' award. NutraIngredients-USA, a world leading digital trade publication, has announced that VitaFiber™ IMO is a finalist.
The Networks of Centres of Excellence (NCE) recently announced its continued support in Canadian glycomics research with a three-year investment of $16.3 million through the Canadian Glycomics Network (GlycoNet).
Edmonton-based biotechnology company CanBiocin Inc. has acquired all of the assets of Denver, CO based Pure Cultures Inc. effective April 30, 2020.
48Hour Discovery Inc. announced it has initiated drug discovery projects for therapeutic targets related to COVID-19. They will use proprietary technology to rapidly develop peptide-based anti-viral compounds for treatment of those infected with COVID-19.
A number of natural health product producers, spirits licensees, licenced users and brewer licensees (excise licensees) have stepped forward in response to COVID-19 with an interest in temporarily expanding their operations to produce hand sanitizer.
The National Research Council Canada is offering life science companies the opportunity to register for two programs: NRC COVID-19 Challenge Program & NRC Industrial Research Assistance Program. Read additional details here.
Edmonton-based Radient Technologies is pleased to enter into a three-way agreement with Allied and the Dhaliwal Group to manage the supply chain, manufacturing and sale of high quality CBD distillate and isolate.
THOUSAND OAKS, Calif., March 23, 2020-Amgen and the Amgen Foundation today announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in communities impacted by the COVID-19 pandemic.
Entos Pharmaceuticals (Entos), a healthcare biotechnology company that develops next generation nucleic acid medicines using the Fusogenix drug delivery platform, today announced their development of a Fusogenix DNA vaccine to prevent COVID-19 infections.
Regenerative medicine is fascinating business. BioTechCanada is asking you to answer the call for the AMGEN BIONATION Regenerative Medicine Innovation Challenge 2020!
See details & requirements for proposals and apply now at www.bionation.ca
Life Sciences Innovation Hub Members and Tenants can access up to 100 hours of free consultancy from a talented roster of 25 Expert Advisors located across Canada and parts of the U.S.